UNSPSC 51372027: Levorphanol tartrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO.C4H6O6.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04WQU6T9QI, chemically known as morphinan-6-ol, n-methyl-, tartrate (1:1) (salt), stereoisomer but more generally known as levorphanol tartrate, which bears US NIH Compound Identifier 260127. European Medicines Agency schedules Levorphanol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02914MIG.

UNSPSC 51372027 Levorphanol tartrate is a Commodity code for a specific opioid pharmaceutical product, but state and local solicitations recently tagged under this code show little alignment with levorphanol itself; instead, they reflect broader pharmaceutical procurement activity spanning naloxone, generic multi-source drugs, and direct-to-manufacturer prescription programs. State and local governments buy pharmaceuticals and medical products through competitive bidding, cooperative purchasing alliances, and information-gathering requests that cover emergency-response medications, over-the-counter items, and prescription-fulfillment infrastructure. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The code shows sparse recent activity with limited direct relevance to levorphanol as a commodity; the tagged opportunities reflect general pharmaceutical procurement rather than this specific drug.

Recent solicitations span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS in June 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with a two-year initial term and one-year renewal option. Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs serving self-insured employee health plans and state agencies. Minnesota MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness, requiring vendors to supply through three authorized wholesalers and maintain compliance with cGMP and DSCSA, effective July 1, 2026. The mismatch between the levorphanol commodity code and actual procurement scope signals that this code has minimal current relevance to active state and local buying activity.